KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Travere Therapeutics (TVTX) Accumulated Depreciation & Amortization: 2016-2024

Historic Accumulated Depreciation & Amortization for Travere Therapeutics (TVTX) over the last 1 years, with Dec 2024 value amounting to $8.8 million.

  • Travere Therapeutics' Accumulated Depreciation & Amortization rose 17.63% to $8.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $24.4 million, marking a year-over-year increase of 24.55%. This contributed to the annual value of $43.6 million for FY2024, which is 13.04% up from last year.
  • As of Q4 2024, Travere Therapeutics' Accumulated Depreciation & Amortization stood at $8.8 million, which was up 17.63% from $7.4 million recorded in Q4 2023.
  • In the past 5 years, Travere Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $8.8 million in Q4 2024 and a low of $3.0 million during Q4 2021.
  • In the last 3 years, Travere Therapeutics' Accumulated Depreciation & Amortization had a median value of $7.4 million in 2023 and averaged $7.1 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first spiked by 113.97% in 2020, then dropped by 22.58% in 2021.
  • Travere Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $3.9 million in 2020, then declined by 22.58% to $3.0 million in 2021, then surged by 70.44% to $5.2 million in 2022, then soared by 43.27% to $7.4 million in 2023, then grew by 17.63% to $8.8 million in 2024.
  • Its Accumulated Depreciation & Amortization stands at $8.8 million for Q4 2024, versus $7.4 million for Q4 2023 and $5.2 million for Q4 2022.